pone.0266478.g005.tif (1.47 MB)
CB-5083 and cytarabine or venetoclax synergistically decrease AML cell survival.
figure
posted on 2022-04-06, 17:39 authored by Paweł P. Szczęśniak, Jan B. Heidelberger, Hubert Serve, Petra Beli, Sebastian A. Wagner(A-D) THP-1 and MV4-11 cell survival was assessed in a 96-well format with increasing concentrations of CB-5083 and cytarabine or venetoclax. Following a 72-hour incubation, CellTiter-Blue Reagent was added and fluorescence/cell viability was assessed. Cell viability data was used as input for the SynergyFinder software to estimate synergy δ scores. Synergy landscape maps display δ scores for the indicated cells lines and drug combinations.
History
Usage metrics
Categories
Keywords
relevant therapeutic strategyheterogeneous malignancy characterizedacute myeloid leukemiaabundant molecular chaperoneresistance possibly limitextracts ubiquitylated substratescellular compartments priorunfolded protein responsediv >< paml cell linesvcp inhibitor cbvcp inhibition inducesubiquitylated proteinsresistance mediatedcellular ubiquitinprotein complexescontaining proteinvcp leadsvcp inhibitorsvcp inhibitionvcp taken togethermodified proteomemimetic venetoclaxdependent mannerbone marrowbased proteomicsantimetabolite cytarabineanimal modelsaml cellsacts synergistically5083 leads5083 decreases
